Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups

详细信息    查看全文

• 作者：Weihong Ding ; Shijun Tong ; Yuancheng Gou ; Chuanyu Sun…
• 关键词：Non ; muscle ; invasive bladder cancer ; HER ; 2 ; EORTC ; Prognosis ; Immunohistochemistry
• 刊名：World Journal of Urology
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：33
• 期：12
• 页码：1951-1957
• 全文大小：819 KB
• 参考文献：1.Parkin MD, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74鈥?08CrossRef PubMed
  2.Babjuk M et al (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997鈥?008CrossRef PubMed
  3.Kurth KH et al (1995) Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 31A:1840鈥?846CrossRef PubMed
  4.Allard P et al (1998) The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 81:692鈥?98CrossRef PubMed
  5.Soloway MS (2007) It is time to abandon the 鈥渟uperficial鈥?in bladder cancer. Eur Urol 52:1564鈥?565CrossRef PubMed
  6.Bryan RT, Wallace DM (2002) 鈥漇uperficial鈥?bladder cancer鈥攖ime to uncouple pT1 tumours from pTa tumours. BJU Int 90:846鈥?52CrossRef PubMed
  7.Sylvester RJ et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466鈥?77CrossRef PubMed
  8.Ding Weihong et al (2014) Are EORTC risk tables suitable for Chinese patients with non-muscle-invasive bladder cancer? Cancer Epidemiol 38:157鈥?61CrossRef PubMed
  9.Sylvester RichardJ (2011) How well can you actually predict which non-muscle-invasive bladder cancer patients will progress? Eur Urol 60:431鈥?34CrossRef PubMed
  10.King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974鈥?76CrossRef PubMed
  11.Olayioye MA et al (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159鈥?167PubMedCentral CrossRef PubMed
  12.Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl. 2):1鈥?3CrossRef PubMed
  13.Sato K et al (1992) An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 70:2493鈥?498CrossRef PubMed
  14.Chow NH et al (2001) Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7:1957鈥?962PubMed
  15.Gandour-Edwards R et al (2002) Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95:1009鈥?015CrossRef PubMed
  16.Latif Z et al (2003) HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 89:1305鈥?309PubMedCentral CrossRef PubMed
  17.Latif Z et al (2004) HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 40:56鈥?3CrossRef PubMed
  18.Coogan CL et al (2004) HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 63:786鈥?90CrossRef PubMed
  19.Kruger S et al (2005) Protein expression and gene copy number analysis of topoisomerase 2a, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder鈥攁 multitissue array study with prognostic implications. Anticancer Res 25(1A):263鈥?71PubMed
  20.Kolla SB et al (2008) Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 40:321鈥?27CrossRef PubMed
  21.Kassouf W et al (2008) Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 179:353鈥?58PubMedCentral CrossRef PubMed
  22.Liedberg F et al (2008) Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol 26:17鈥?4CrossRef PubMed
  23.Bolenz C et al (2010) Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int 106:1216鈥?222CrossRef PubMed
  24.Lammers RianneJM, Witjes Alfred (2011) Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues. Expert Rev Anticancer Ther 11:853鈥?58CrossRef PubMed
  25.Greene FL et al (2002) AJCC cancer staging Manual, 6th edn. Springer, New York, p 2002CrossRef
  26.Chen Z et al (2012) The 1973 WHO classification is more suitable than the 2004 WHO classification for predicting prognosis in non-muscle-invasive bladder cancer. PLoS One 7:e47199. doi:10.鈥?371/鈥媕ournal.鈥媝one.鈥?047199 PubMedCentral CrossRef PubMed
  27.Schrier BP et al (2004) Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumors and implications for therapy. Eur Urol 45:292鈥?96CrossRef PubMed
  28.Chen PC, Yu HJ, Chang YH, Pan CC (2013) Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol 66:113鈥?19CrossRef PubMed
  29.Olsson H, Fyhr IM, Hultman P, Jahnson S (2012) HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder. Scand J Urol Nephrol 46:102鈥?07CrossRef PubMed
  30.Lae M et al (2010) Assessing HER-2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 21:815鈥?19PubMedCentral CrossRef PubMed
  31.Denzinger S et al (2008) Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 53:146鈥?52CrossRef PubMed
  
• 作者单位：Weihong Ding (1)
  Shijun Tong (1)
  Yuancheng Gou (1)
  Chuanyu Sun (1)
  Hong Wang (2)
  Zhongqing Chen (2)
  Jun Tan (3)
  Ke Xu (1)
  Guowei Xia (1)
  Qiang Ding (1)
  
  1. Department of Urology, Huashan Hospital, Fudan University, No. 12 Middle Urumqi Road, Shanghai, 200040, China
  2. Department of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, China
  3. Department of Biostatistics and Social Medicine, School of Public Health, Fudan University, Shanghai, 200032, China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Urology and Andrology
  Nephrology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-8726

文摘

Purpose Current pathological and clinical parameters provide important prognostic information. However, they are still limitations for predicting the true malignant potential of a specific cancer. The aim of this study was to validate the predicting role of HER-2 expression and demonstrated that combination of the high-risk factors with HER-2 expression is more valuable for determining which non-muscle-invasive bladder cancer (NMIBC) is more aggressive.